Immune therapy added to chemotherapy improves pathological complete response in patients with early triple negative breast cancer, according to new results from the KEYNOTE-522 trial. Interim results from the study, which is the first phase III trial of immunotherapy in early breast cancer, also indicated an improvement in event-free survival.
Read moreIn the prospective TAILORx trial, 93% of women with hormone-sensitive, HER2-negative, axillary node-negative breast cancer and a high Recurrence Score 26-100 were estimated to be cancer-free at five years. This outcome was much better than expected with endocrine therapy alone. The finding adds to limited data on outcomes with a high RS of 26-100, treated with taxane and/or anthracycline-containing chemotherapy plus endocrine therapy. It adds to the body of evidence supporting use of the RS.
Read moreFlavor, safety and family attitude toward vaping are among the greatest factors influencing teenage perception of e-cigarettes, new research finds.
Read moreWhole genome sequencing of tumour cells could help predict the prognosis of a patient's cancer and offer clues to identify the most effective treatment, suggests an international study.
Read moreA new mechanism makes it possible to understand premature ageing in cells with asymmetrical cell division, as is the case with mother cells. Understanding this mechanism is useful for studying and, in the future, anticipating the development of ageing-related diseases, such as cancer and neurodegenerative processes.
Read morePatients with mesothelioma may gain similar benefit from immunotherapy as chemotherapy, and good responders may provide important clues to novel treatment for the thousands of new cases each year. New data highlight the need to understand the biological mechanisms whereby mesothelioma, which is incurable, adapts to immunotherapy in some patients but not in others, resulting in variations in treatment response.
Read moreX-rays could be tuned to deliver a more effective punch that destroys cancer cells and not harm the body.
Read moreNew research found that oncogene SET/TAF1, which was found to be a proto-oncogene of acute myeloid leukemia (AML), contributes to proper chromosome partitioning as a tension sensor. Additionally, abnormal SET protein disrupts tension sensor system at the centromere, leading to missegregation of the chromosomes and thereby cancer. These findings may lead to a discovery for a new kind of leukemia treatment.
Read moreA new blood test in development has shown ability to screen for numerous types of cancer with a high degree of accuracy, a trial of the test shows.
Read moreA cluster of interacting proteins that are active in both human cancers and Tasmanian devil facial tumours, may give clues to how cancers evade the immune system, according to a new study.
Read more